<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271582</url>
  </required_header>
  <id_info>
    <org_study_id>CPT_08_001</org_study_id>
    <nct_id>NCT01271582</nct_id>
  </id_info>
  <brief_title>Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients</brief_title>
  <official_title>Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the association between UGT1A1 polymorphisms and
      neutropenia and diarrhea in Korean patients with advanced colorectal or gastric cancer
      treated with FOLFIRI regimen.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>During the first cycle of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between UGT1A1 polymorphism and grade 3/4 neutropenia in all treatment duration</measure>
    <time_frame>24 weeks</time_frame>
    <description>During all treatment period(during 12 cycle, each 2 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between grade 3/4 diarrhea and UGT1A1 polymorphism</measure>
    <time_frame>2 weeks</time_frame>
    <description>During the first cycle of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months (average)</time_frame>
    <description>The time from registration to objective tumor progression or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Stage IV Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan, 5FU, leucovorin</intervention_name>
    <description>FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>CAMPTO (CAMPOSAR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Subjects should meet all of the following criteria to participate in the
        trial.

          -  Histologically confirmed colorectal or gastric cancer patients who are chemonaive or
             failed to 1st line chemotherapy

          -  Subjects who are expected to receive toxicity test at least once after FOLFIRI
             treatment.

          -  Aged 18 years or older.

          -  ECOG performance status of ≤ 2.

          -  Anticipated life expectancy of ≥ 3 months.

          -  Clinically acceptable function of bone marrow, kidney and liver function as below.

               1. ANC ≥ 1500/mm3 and platelet count ≥ 100,000/mm3

               2. Serum total bilirubin ≤ 1.5 x ULN, alkaline phosphatase ≤ 2.5 x ULN, Serum ALT
                  and AST ≤ 2.5 x ULN (Serum ALT and AST ≤ 5 x ULN, if liver metastases are
                  present)

               3. Serum creatinine ≤ 1.5 mg/dL or CLcr &gt; 60 ml/min

          -  Subjects whose written informed consent can be obtained prior to their participation
             in the trial.

        Exclusion Criteria: Subjects who meet any of the following criteria should not be included
        in the trial.

          -  Pregnant or breast feeding women

          -  Serious concurrent complication, severe active infection.

          -  Subjects with chronic diarrhea, paralytic ileums, pulmonary fibrosis or pneumonia
             interstitialis

          -  Subjects with epilepsia or severe psychiatric disorders.

          -  Subjects who are regarded to be unsuitable for this trial by the investigator.

          -  Subjects who are participating in other clinical trials

          -  Subjects who have received prior chemotherapy including irinotecan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YongSang Hong, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hwasun Hospital</name>
      <address>
        <city>Chŏnam</city>
        <state>Hwasun-gun</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Nowon-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Tae Won Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colorecatal cancer</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>UGT1A1</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

